<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02026271</url>
  </required_header>
  <id_info>
    <org_study_id>ATI001-102</org_study_id>
    <nct_id>NCT02026271</nct_id>
  </id_info>
  <brief_title>A Study of Ad-RTS-hIL-12 With Veledimex in Subjects With Glioblastoma or Malignant Glioma</brief_title>
  <official_title>A Phase I Study of Ad-RTS-hIL-12, an Inducible Adenoviral Vector Engineered to Express hIL-12 in the Presence of the Activator Ligand Veledimex in Subjects With Recurrent or Progressive Glioblastoma or Grade III Malignant Glioma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ziopharm</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ziopharm</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This research study involves an investigational product: Ad-RTS-hIL-12 given with veledimex&#xD;
      for production of human IL-12. IL-12 is a protein that can improve the body's natural&#xD;
      response to disease by enhancing the ability of the immune system to kill tumor cells and may&#xD;
      interfere with blood flow to the tumor.&#xD;
&#xD;
      The main purpose of this study is to evaluate the safety and tolerability of a single tumor&#xD;
      injection of Ad-RTS-hIL-12 given with oral veledimex.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Eligible patients will be stratified to one of two groups, according to clinical indication&#xD;
      for tumor resection. Patients who are scheduled for a standard of care craniotomy and tumor&#xD;
      resection will receive one dose of veledimex before the resection procedure. Ad-RTS-hIL-12&#xD;
      will be administered by free-hand injection. Patients will continue on oral veledimex for 14&#xD;
      days.&#xD;
&#xD;
      Patients not scheduled for tumor resection will receive Ad-RTS-hIL-12 by stereotactic&#xD;
      injection and then will continue on oral veledimex for 14 days.&#xD;
&#xD;
      The study is divided into three periods: the screening period, the treatment period and the&#xD;
      follow-up period.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2015</start_date>
  <completion_date type="Actual">August 2019</completion_date>
  <primary_completion_date type="Actual">August 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability of varying doses of intratumoral Ad-RTS-hIL-12 and oral veledimex doses in subjects with recurrent or progressive glioblastoma or Grade III malignant glioma</measure>
    <time_frame>3 years</time_frame>
    <description>Evaluation will be based on the incidence, intensity, and type of Adverse Events (AEs). Clinically significant changes in the subjects' physical examinations, vital signs, and ECG evaluations, and clinical manifestations relevant to abnormal laboratory values will be captured as AEs.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Veledimex maximum tolerated dose (MTD) when given with varying doses of intratumoral Ad-RTS-hIL-12</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Veledimex pharmacokinetic profile and veledimex concentration ratio between the brain tumor and the blood</measure>
    <time_frame>3 years</time_frame>
    <description>Veledimex PK parameters to be determined will include, but are not limited to, the maximum plasma concentration (Cmax), time to maximum plasma concentration (Tmax), half-life (t1/2), area-under-the-concentration versus time curve (AUC), volume of distribution (Vd), and clearance (CL). Where possible, descriptive statistics of the PK parameters will be provided; individual subject veledimex concentrations, actual sampling times, and PK parameters will be listed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cellular and humoral immune responses elicited by Ad-RTS-hIL-12 and veledimex</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumor Objective Response Rate (ORR)</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Glioblastoma Multiforme</condition>
  <condition>Anaplastic Oligoastrocytoma</condition>
  <arm_group>
    <arm_group_label>Ad-RTS-hIL-12+veledimex</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>varying doses of intratumoral Ad-RTS-hIL-12 (INXN-2001) and oral veledimex (activator ligand).</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Ad-RTS-hIL-12</intervention_name>
    <description>2.0 x 10^11 viral particles (vp) per injection or 1.0 x 10^12 viral particles (vp) per injection&#xD;
one intratumoral injection of Ad-RTS-hIL-12</description>
    <arm_group_label>Ad-RTS-hIL-12+veledimex</arm_group_label>
    <other_name>INXN-2001</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>veledimex</intervention_name>
    <description>4 doses (20mg/day, 40mg/day, 80mg/day, and 120mg/day)&#xD;
14 oral daily doses of veledimex&#xD;
1 Expansion cohort at a single dose level at or below MTD</description>
    <arm_group_label>Ad-RTS-hIL-12+veledimex</arm_group_label>
    <other_name>INXN-1001</other_name>
    <other_name>Activator Ligand</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or female subjects ≥ 18 and ≤ 75 years of age&#xD;
&#xD;
          2. Provision of written informed consent for tumor resection, stereotactic surgery, tumor&#xD;
             biopsy, samples collection and treatment with investigational products prior to&#xD;
             undergoing any study procedures&#xD;
&#xD;
          3. Histologically confirmed supratentorial glioblastoma or other WHO grade III or IV&#xD;
             malignant glioma from archival tissue.&#xD;
&#xD;
          4. Evidence of tumor recurrence/progression by MRI (RANO criteria) post standard initial&#xD;
             therapy.&#xD;
&#xD;
          5. Previous standard of care anti-tumor treatment including surgery and/or biopsy and&#xD;
             chemoradiation. The washout periods from prior therapies are intended as follows:&#xD;
&#xD;
               1. Nitrosoureas: 6 weeks&#xD;
&#xD;
               2. Other cytotoxic agents: 4 weeks&#xD;
&#xD;
               3. Anti-angiogenic agents including bevacizumab: 4 weeks&#xD;
&#xD;
               4. Targeted agents including small-molecule tyrosine kinase inhibitors: 2 weeks&#xD;
&#xD;
               5. Experimental immunotherapies: 3 months&#xD;
&#xD;
               6. Vaccine based therapy: 3 months&#xD;
&#xD;
          6. Able to undergo standard MRI scans with contrast agent&#xD;
&#xD;
          7. Karnofsky Performance Status ≥ 70&#xD;
&#xD;
          8. Adequate bone marrow reserves and liver and kidney function, as assessed by the&#xD;
             following laboratory requirements:&#xD;
&#xD;
               1. Hemoglobin ≥ 9 g/L&#xD;
&#xD;
               2. Lymphocytes &gt; 500/ mm3&#xD;
&#xD;
               3. Absolute Neutrophil Count ≥ 1500/ mm3&#xD;
&#xD;
               4. Platelets ≥ 100,000/ mm3&#xD;
&#xD;
               5. Serum creatinine ≤ 1.5 x ULN&#xD;
&#xD;
               6. AST (SGOT) and ALT (SGPT) ≤ 2.5 x ULN. For subjects with documented liver&#xD;
                  metastases, ALT and AST ≤ 5 × ULN&#xD;
&#xD;
               7. Total bilirubin &lt; 1.5 x ULN&#xD;
&#xD;
               8. International Normalized Ratio (INR) and activated Partial Thromboplastin Time&#xD;
                  [PTT] within normal institutional limits&#xD;
&#xD;
          9. Male and female subjects must agree to use a highly reliable method of birth control&#xD;
             (expected failure rate less than 5% per year) from the screening visit through 28 days&#xD;
             after the last dose of study drug. Women of childbearing potential must have a&#xD;
             negative pregnancy test at screening.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Radiotherapy within 4 weeks or less prior to starting first veledimex dose&#xD;
&#xD;
          2. Subjects with clinically significant increased intracranial pressure or uncontrolled&#xD;
             seizures.&#xD;
&#xD;
          3. Known immunosuppressive disease, autoimmune conditions, and /or chronic viral&#xD;
             infections&#xD;
&#xD;
          4. Use of systemic antibacterials, antifungals or antivirals for the treatment of acute&#xD;
             clinically significant infection within 2 weeks of first veledimex dose. Concomitant&#xD;
             therapy for chronic infections is not allowed. Subjects must be afebrile prior to&#xD;
             Ad-RTS-hIL-12 injection; only prophylactic antibiotic use is permitted&#xD;
             perioperatively.&#xD;
&#xD;
          5. Use of enzyme-inducing anti-epileptic drugs (EIAED) within 7 days prior to the first&#xD;
             dose of study drug.&#xD;
&#xD;
          6. Other concurrent clinically active malignant disease, requiring treatment, with the&#xD;
             exception of non-melanoma cancers of the skin or carcinoma in-situ of the cervix or&#xD;
             non-metastatic prostate cancer.&#xD;
&#xD;
          7. Nursing or pregnant females&#xD;
&#xD;
          8. Prior exposure to veledimex&#xD;
&#xD;
          9. Use of medications that induce, inhibit or are substrates of CYP450 3A4 within 7 days&#xD;
             prior to the first veledimex dosing&#xD;
&#xD;
         10. Presence of any contra-indication for a neurosurgical procedure&#xD;
&#xD;
         11. Unstable or clinically significant concurrent medical condition that would, in the&#xD;
             opinion of the investigator or medical monitor, jeopardize the safety of a subject&#xD;
             and/or their compliance with the protocol.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Arnold Gelb, MD</last_name>
    <role>Study Director</role>
    <affiliation>Ziopharm Oncology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cedars-Sinai</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California - San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwestern</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brigham &amp; Women's</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>December 16, 2013</study_first_submitted>
  <study_first_submitted_qc>December 30, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 1, 2014</study_first_posted>
  <last_update_submitted>September 21, 2021</last_update_submitted>
  <last_update_submitted_qc>September 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioblastoma</mesh_term>
    <mesh_term>Glioma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

